Home Urine Tumor Markers NMP22 Urine Test: Bladder Cancer Marker, High Levels, and Recurrence Monitoring

NMP22 Urine Test: Bladder Cancer Marker, High Levels, and Recurrence Monitoring

By
Vita Library
-
1
Understand the NMP22 urine test for bladder cancer, including the 10 U/mL cutoff, high results, false positives, BladderChek accuracy, and recurrence monitoring.

The NMP22 urine test looks for nuclear matrix protein 22, a protein-related signal that can increase in urine when urothelial cells are turning over rapidly, including in bladder cancer. Two main formats have been used: a quantitative laboratory assay that reports a concentration and the NMP22 BladderChek point-of-care test, which gives a qualitative positive or negative result around a defined cutoff. An elevated or positive NMP22 result can increase suspicion for bladder cancer, but it is not specific enough to diagnose cancer by itself. Blood in the urine, urinary infection, stones, inflammation, and recent urinary procedures can also increase urinary cellular breakdown and contribute to false-positive results. NMP22 sensitivity also varies widely and is generally poorer for low-grade, low-stage tumors. For these reasons, current evidence supports NMP22 as an adjunct in selected situations rather than a replacement for cystoscopy, urine cytology, imaging, or biopsy when those tests are indicated.

  • NMP22 is a urinary protein marker associated with increased urothelial-cell turnover; bladder tumors can release more of it into urine.
  • A commonly used historical cutoff is 10 U/mL, and the BladderChek format is interpreted as positive or negative rather than as a detailed cancer-risk score.
  • High NMP22 does not prove bladder cancer. Hematuria, infection, stones, inflammation, and recent instrumentation can produce false-positive results.
  • A negative NMP22 result cannot rule out bladder cancer, especially low-grade or small tumors that may shed less marker.
  • NMP22 should complement, not replace, standard evaluation and surveillance. Cystoscopy remains central when bladder cancer is suspected or being monitored.

Table of Contents

What the NMP22 Urine Test Measures

NMP22 stands for nuclear matrix protein 22. Nuclear matrix proteins help organize structures within the cell nucleus and participate in processes related to cell division. Urothelial cancer cells tend to have rapid and disordered turnover, and cellular breakdown can release increased amounts of NMP22-related material into urine.

That biological link made NMP22 attractive as a noninvasive bladder cancer marker. A urine sample is easy to obtain, and an immunoassay can detect the marker without inserting an instrument into the bladder. However, the same mechanism creates an important weakness: cancer is not the only cause of urothelial-cell injury or cell death.

Bladder inflammation, bleeding, infection, stones, and mechanical irritation can also increase cellular material in urine. NMP22 therefore behaves more like a marker of abnormal urothelial turnover than a uniquely cancer-specific molecule.

The main clinical target is urothelial carcinoma of the bladder. The test cannot show where a lesion is located, how deeply it invades the bladder wall, whether lymph nodes are involved, or what the tumor grade is. Those questions require direct visualization, imaging, and pathology.

NMP22 also differs from urine cytology. Cytology looks directly at the appearance of shed urinary cells, while NMP22 measures a protein-related signal. It also differs from molecular tests such as UroVysion FISH, which detects specified chromosome changes in urinary cells.

The practical implication is simple: NMP22 can add information, but the result must be connected to the reason the test was ordered and to the rest of the urologic evaluation.

Quantitative NMP22 and BladderChek

NMP22 has been measured in two broadly different formats.

Quantitative laboratory NMP22 assays use immunoassay methods to report a numerical concentration, generally in units per milliliter (U/mL). Older studies often used 10 U/mL as a reference cutoff, but research has used other thresholds as well. Absolute values can vary with the assay and patient population, so a number should be interpreted using the performing laboratory’s method and reference information.

NMP22 BladderChek is a rapid lateral-flow immunoassay designed to provide a qualitative result. The classic test uses approximately 10 U/mL as the positive threshold. Instead of using the exact concentration to estimate stage or risk, the test indicates whether NMP22 is detected above the assay’s cutoff.

The U.S. Food and Drug Administration has authorized the BladderChek test as an aid in diagnosing and monitoring bladder cancer in conjunction with standard diagnostic procedures. That wording is important. Regulatory authorization does not mean the assay can replace cystoscopy or establish a diagnosis independently.

A point-of-care format offers convenience because results can be available during a clinical visit. But speed does not overcome the biological limitations of the marker. A positive result still has to be interpreted in light of hematuria, infection, recent catheterization, stone disease, and cancer history.

For patients, the distinction between “10 U/mL or higher” and “cancer present” is essential. The cutoff is a test threshold, not a boundary between healthy and malignant tissue. Some people without cancer will test positive, and some people with cancer will test negative.

When reviewing an old record, also check which NMP22 assay was used. A quantitative laboratory value and a qualitative BladderChek result should not be treated as interchangeable reports even though they target the same marker.

Collection conditions deserve attention as well. Many clinical studies used freshly voided urine obtained before cystoscopy, and point-of-care testing is intended to be performed according to the device instructions. A sample visibly contaminated with blood or obtained during an active urinary problem may carry a different false-positive risk from a routine sample in an otherwise stable patient. Patients should not try to manipulate hydration to “improve” the result; instead, they should follow the collection directions and tell the clinician about current urinary symptoms, antibiotics, recent catheterization, procedures, or stone episodes. Those details can be more important to interpretation than small differences in a quantitative NMP22 concentration.

What High or Positive NMP22 Means

A high NMP22 concentration or positive BladderChek result means that the urine contains an increased NMP22 signal. In someone with visible or microscopic blood in the urine, it may raise concern that a urothelial tumor is contributing to abnormal cell turnover.

The result does not tell the clinician how likely cancer is without context. The positive predictive value depends strongly on the population. A positive test in a person already known to have recurrent bladder tumors carries different meaning from a positive test in a low-risk person with a temporary urinary infection.

Higher NMP22 values have sometimes correlated with larger, higher-grade, or more advanced tumors in studies, but there is too much overlap to use the value as a stage or grade measurement. A concentration of 30 U/mL is not “three times as cancerous” as 10 U/mL, and a very high result does not establish muscle invasion.

A useful way to interpret an abnormal result is to ask four questions:

  1. Why was the test ordered? Hematuria evaluation and recurrence surveillance have different pretest risks.
  2. Was there a benign confounder? Infection, stones, bleeding, inflammation, or recent instrumentation can matter.
  3. What did the other tests show? Cystoscopy, cytology, imaging, and pathology carry different types of evidence.
  4. Would the result change management? An abnormal urine marker is most useful when it identifies a need for additional evaluation rather than merely repeating information already known.

If NMP22 is high while BTA stat or another marker is negative, the tests should not be “voted” against each other. Different assays have different analytes, sensitivity patterns, and susceptibility to false positives. Clinical evaluation remains the tie-breaker.

False Positives, False Negatives, and Test Limits

The biggest practical limitation of NMP22 is that both false-positive and false-negative results are common enough to affect care.

False positives can occur when noncancer conditions increase urinary cell damage or add cellular material to the sample. Potential confounders include:

  • urinary tract infection;
  • visible or substantial microscopic hematuria;
  • kidney or bladder stones;
  • inflammatory urinary conditions;
  • recent catheterization or cystoscopy;
  • recent urinary surgery or instrumentation; and
  • other causes of urothelial irritation.

This is why timing can matter. If a patient has an active infection or has just undergone an invasive urinary procedure, a clinician may prefer to address the confounder before relying on a urinary protein marker.

False negatives occur for different reasons. A small tumor may shed little marker. Low-grade papillary tumors often have less aggressive cell turnover and are particularly likely to be missed. Marker release may also fluctuate, and urine sampling captures only one point in time.

Specimen handling and assay performance add another layer. Concentrated or dilute urine, collection timing, storage, and laboratory technique can influence quantitative measurements. Point-of-care tests avoid some processing steps but still depend on correct collection and interpretation.

NMP22 should also not be used as a general population screening test simply because it is noninvasive. In a population where bladder cancer is uncommon, false positives can outnumber true positives and lead to unnecessary cystoscopies or anxiety. Evidence and guidelines have not established NMP22 as a stand-alone screening strategy for asymptomatic average-risk adults.

A negative result is therefore not a reason to ignore visible blood in the urine. Hematuria can be caused by many benign conditions, but it can also signal bladder or upper-tract cancer and should be evaluated according to clinical risk.

Accuracy and Why Tumor Grade Matters

NMP22 performance varies widely across studies. An older meta-analysis of the BladderChek test reported pooled sensitivity of about 56% and specificity of about 88%. Sensitivity increased with higher tumor stage and grade, which is a recurring pattern in urinary biomarker research.

A large German multicenter study published in 2023 illustrates that variability in a contemporary real-world cohort. NMP22 BladderChek sensitivity was only 13.4% for low-grade tumors, about 49.5% for high-grade non-muscle-invasive tumors, and 35.2% for high-grade muscle-invasive tumors, while specificity was 95.5%. These figures differ from earlier pooled estimates and show why one headline sensitivity number should not be assumed for every setting.

Why can low-grade tumors be difficult? Low-grade papillary bladder cancers may grow with less cell death and less release of nuclear proteins into urine. By contrast, higher-grade tumors often have more disordered growth and turnover, producing a stronger urinary signal. Even then, NMP22 does not detect all high-grade disease.

Systematic reviews published in 2023 and 2024 reached a consistent practical conclusion: urinary biomarkers can have complementary value, but current assays have not shown enough reliable accuracy to supplant cystoscopy as the diagnostic standard.

That tradeoff also differs from cytology. Cytology is often highly specific and performs better for many high-grade cancers, while its sensitivity is poor for low-grade disease. NMP22 may detect some tumors missed by cytology but can produce more false positives. Combining tests can improve sensitivity in some studies, yet increased testing can also reduce specificity and create more follow-up procedures.

Specificity also changes when investigators exclude or include people with known confounding conditions. A study that removes patients with urinary infection, stones, heavy hematuria, or recent instrumentation can make a protein marker look cleaner than it will in everyday hematuria practice. This partly explains why performance numbers from different studies can appear inconsistent even when they are all technically correct for their own populations.

The correct question is therefore not “Is NMP22 accurate?” but “How accurate is this assay in a patient like me, for this exact clinical purpose, and what will be done with the result?”

NMP22 for Bladder Cancer Recurrence Monitoring

Bladder cancer—especially non-muscle-invasive bladder cancer—often requires long-term surveillance because tumors can recur. That has made a simple urine marker appealing as a way to reduce the burden of repeated cystoscopy.

NMP22 has been studied for recurrence detection, and a rising or positive result can raise concern in a patient with a prior tumor. However, recurrence surveillance is precisely where a false-negative result can be dangerous. A negative NMP22 test does not reliably exclude recurrent cancer, so it should not automatically cancel a scheduled cystoscopy.

Current guideline-based surveillance is risk-adjusted. A patient with previous high-grade T1 disease or carcinoma in situ has a very different recurrence and progression risk from someone with a single small low-grade Ta tumor. Urine marker results cannot erase those baseline differences.

A 2025 systematic review of urinary biomarkers in non-muscle-invasive bladder cancer surveillance found wide variation in sensitivity and specificity across tests and concluded that biomarkers may complement rather than replace cystoscopy. Newer genetic and molecular assays may eventually support less invasive surveillance strategies in selected groups, but standardized protocols still require further validation.

NMP22 may be most useful when it is part of a planned decision pathway—for example, as an adjunct to cystoscopy and cytology rather than as an isolated home check. If a marker becomes positive after previous negative results, the clinician may look more carefully for recurrence, but the marker alone cannot determine whether a lesion is present or whether it needs resection.

Patients should also report new symptoms between surveillance visits. Visible hematuria, worsening urinary urgency, painful urination, or other persistent changes can justify evaluation even if the most recent NMP22 result was negative.

What to Do With an NMP22 Result

After a positive or high NMP22 result, the first step is to review possible benign explanations and the reason testing was performed. A urine culture may be appropriate when infection is suspected. The clinician may also review whether the sample was collected soon after cystoscopy, catheterization, stone passage, or another source of urinary tract injury.

If cancer remains a concern, the next step is usually standard urologic evaluation rather than repeating NMP22 until it becomes negative. Depending on the situation, this can include cystoscopy, cytologic examination of urine, upper-tract imaging, or biopsy/resection of a visible lesion.

After a negative result, follow-up depends on baseline risk. A low-risk patient with a reassuring complete evaluation may need only the follow-up recommended for that clinical scenario. A high-risk surveillance patient generally continues scheduled cystoscopy despite a negative marker.

If results are repeatedly discordant—for example, NMP22 is positive but cystoscopy and cytology are negative—the clinician may consider whether inflammation or another confounder is present and whether repeat or enhanced evaluation is justified. The correct response depends on cancer history and overall risk rather than on the marker alone.

Questions worth asking include:

  • Which NMP22 format did I have: quantitative laboratory testing or BladderChek?
  • What cutoff did this laboratory use?
  • Could blood, infection, stones, or a recent procedure have affected my result?
  • Does this result change whether I need cystoscopy?
  • If I have a history of bladder cancer, does my original tumor grade or stage make a negative result less reassuring?

If the NMP22 result comes from an older record, its usefulness may also depend on what has happened since the sample was collected. A marker value from months or years ago cannot substitute for current evaluation when new hematuria or urinary symptoms develop. Bladder cancer risk changes over time, especially after prior tumors, and surveillance decisions should use current clinical information.

NMP22 is most useful when it adds a piece of information to an established diagnostic or surveillance plan. It should not become the plan itself.

References

Disclaimer

This article is for general education and does not diagnose bladder cancer or replace individualized urologic care. NMP22 results can be affected by benign urinary conditions and must be interpreted with symptoms, cystoscopy, cytology, imaging, and cancer history. Visible blood in the urine or concerning urinary symptoms deserve medical evaluation even when an NMP22 result is negative.

RELATED ARTICLESMORE FROM AUTHOR